More Changes In Carcinogenesis Program At NCI: Gori, Workshops Out, Branch Chiefs Running It
In Brief: NCI Can Proceed With Grant, Contract Awards At Full FY 1978 Level; Rundles Heads ACS
Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans
First analysis From Profiles Reveal New Data On Centers
New research Suggested For Immunobiology
NCI Offers Chlorozotocin
To Industry for Development, NDA
Drug Development Gets Extra $500,000
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”